Previous 10 | Next 10 |
MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a firesi...
IGM Biosciences (IGMS) appointed 20-years industry veteran George A. Gauthier to the newly created position of Chief Commercial Officer.He has experience in global commercial strategy, marketing, sales and product development.Most recently, Mr. Gauthier was VP, Global Prod...
MOUNTAIN VIEW, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of George A. Gauthier to the newly created position of Chi...
IGM Biosciences, Inc. (IGMS) Q4 2020 Earnings Conference Call March 30, 2021 04:30 PM ET Company Participants Fred Schwarzer - President and Chief Executive Officer Misbah Tahir - Chief Financial Officer Bruce Keyt - Chief Scientific Officer Daniel Chen - Chief Medical Officer Conference Call...
IGM Biosciences (IGMS): Q4 GAAP EPS of -$0.79 beats by $0.08.Cash and investments as of December 31, 2020 were $366.3 million, compared to $236.6 million as of December 31, 2019.2021 Guidance: IGM expects full year GAAP operating expenses to be between $175 million and $185 mil...
– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – IND Filing for IGM-7354 Planned in 2021 – – Company to Host Conference Ca...
[[BB]], [[CHWY]], [[IGMS]], [[LULU]], [[PHR]], [[PVH]]For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close
MOUNTAIN VIEW, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2020 financial result...
IGM Biosciences (IGMS) appointed Lisa L. Decker, Ph.D., to the newly created position of Chief Business Officer.She holds 20 years of experience in business development strategy, transactions and alliance management.Most recently, she served as Chief Business Officer at Atreca, where she led ...
MOUNTAIN VIEW, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGM), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Lisa L. Decker, Ph.D., to the newly created position of Chief Bu...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...